1. Home
  2. ABUS vs JBSS Comparison

ABUS vs JBSS Comparison

Compare ABUS & JBSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$5.11

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo John B. Sanfilippo & Son Inc.

JBSS

John B. Sanfilippo & Son Inc.

N/A

Current Price

$72.03

Market Cap

1.0B

ML Signal

N/A

Company Overview

Basic Information
Metric
ABUS
JBSS
Founded
2005
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2008
1994

Fundamental Metrics

Financial Performance
Metric
ABUS
JBSS
Price
$5.11
$72.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$109.00
AVG Volume (30 Days)
4.2M
133.6K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
3.26%
EPS Growth
55.26
4.57
EPS
0.84
5.26
Revenue
$14,083,000.00
$1,175,673,000.00
Revenue This Year
N/A
$5.58
Revenue Next Year
$239.71
N/A
P/E Ratio
$6.14
$13.77
Revenue Growth
128.21
6.18
52 Week Low
$3.50
$59.07
52 Week High
$5.45
$92.08

Technical Indicators

Market Signals
Indicator
ABUS
JBSS
Relative Strength Index (RSI) 61.60 31.18
Support Level $4.99 $68.88
Resistance Level $5.42 $73.75
Average True Range (ATR) 0.14 2.37
MACD -0.00 -0.41
Stochastic Oscillator 54.23 0.91

Price Performance

Historical Comparison
ABUS
JBSS

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About JBSS John B. Sanfilippo & Son Inc.

John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.

Share on Social Networks: